IN2015DN03969A - - Google Patents
Info
- Publication number
- IN2015DN03969A IN2015DN03969A IN3969DEN2015A IN2015DN03969A IN 2015DN03969 A IN2015DN03969 A IN 2015DN03969A IN 3969DEN2015 A IN3969DEN2015 A IN 3969DEN2015A IN 2015DN03969 A IN2015DN03969 A IN 2015DN03969A
- Authority
- IN
- India
- Prior art keywords
- treatments
- methods
- disorders
- neuropathic
- risk
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Anti angiogenic treatments treatments of hyperpermeability disorders treatments of neuropathic and neurodegenerative disorders pain treatments methods of reducing the risk of pre eclampsia and compounds for use in such methods are described.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1218676.3A GB201218676D0 (en) | 2012-10-17 | 2012-10-17 | Anti-angiogenic treatments |
GBGB1218758.9A GB201218758D0 (en) | 2012-10-18 | 2012-10-18 | Compounds |
GB201304694A GB201304694D0 (en) | 2013-03-15 | 2013-03-15 | Compounds |
PCT/GB2013/052716 WO2014060763A1 (en) | 2012-10-17 | 2013-10-17 | Compounds useful for treating ocular neovasculan |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2015DN03969A true IN2015DN03969A (en) | 2015-10-02 |
Family
ID=49518992
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN3969DEN2015 IN2015DN03969A (en) | 2012-10-17 | 2013-10-17 |
Country Status (8)
Country | Link |
---|---|
US (1) | US10301264B2 (en) |
EP (1) | EP2908811B1 (en) |
JP (2) | JP2016504270A (en) |
CN (1) | CN104869990B (en) |
AU (1) | AU2013333657B2 (en) |
ES (1) | ES2858511T3 (en) |
IN (1) | IN2015DN03969A (en) |
WO (1) | WO2014060763A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201406956D0 (en) * | 2014-04-17 | 2014-06-04 | Univ Nottingham | Compounds |
GB201518365D0 (en) * | 2015-10-16 | 2015-12-02 | Exonate Ltd | Compounds |
CA3034547C (en) | 2016-08-24 | 2021-04-13 | National Institute Of Biological Sciences, Beijing | Entacapone-related compounds to treat macular degeneration |
AU2018341084B2 (en) * | 2017-09-27 | 2023-04-13 | Exonate Limited | SRPK1 inhibitors |
GB202010829D0 (en) | 2020-07-14 | 2020-08-26 | Exonate Ltd | Compounds for treatment of neovascular diseases |
CN113769073A (en) * | 2021-10-15 | 2021-12-10 | 杭州鑫伟低碳技术研发有限公司 | Method for treating fundus hemorrhage by using biological enzyme |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1052507A (en) | 1963-06-26 | |||
ID29244A (en) | 1998-08-20 | 2001-08-16 | Agouron Pharma | NON-PEPTID GnRH SUBSTANCE, METHODS AND SUBSTANCE BETWEEN THEIR PRODUCTION |
FR2840314B1 (en) | 2002-06-03 | 2004-08-20 | Inst Francais Du Petrole | THERMAL INSULATION METHOD, PROCESS FOR PREPARING AN INSULATING GEL AND INSULATING GEL OBTAINED |
WO2005063293A1 (en) * | 2003-12-26 | 2005-07-14 | Masatoshi Hagiwara | Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient |
MXPA06012613A (en) * | 2004-05-07 | 2007-01-31 | Amgen Inc | Protein kinase modulators and method of use. |
US7776869B2 (en) * | 2004-10-18 | 2010-08-17 | Amgen Inc. | Heteroaryl-substituted alkyne compounds and method of use |
WO2007072041A1 (en) * | 2005-12-23 | 2007-06-28 | Astex Therapeutics Limited | Therapeutic compounds |
WO2008011077A2 (en) | 2006-07-18 | 2008-01-24 | Thule Sweden Ab | System and method for providing an article organizer to a recreational vehicle |
CA2673299C (en) * | 2006-12-21 | 2016-04-12 | Sloan-Kettering Institute For Cancer Research | Pyridazinone compounds for the treatment of proliferative diseases |
GB0704678D0 (en) * | 2007-03-09 | 2007-04-18 | Univ Bristol | Pro- and anti-angiogenic treatments |
US20090069288A1 (en) * | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
WO2009020198A1 (en) | 2007-08-03 | 2009-02-12 | Kinopharma, Inc. | Aniline derivative having anti-dna virus activity |
CN101422603A (en) * | 2007-10-31 | 2009-05-06 | 马万超 | Insoluble biological activity protein as vitreous body oral medicine for treating ophthalmic diseases |
GB0803912D0 (en) | 2008-02-29 | 2008-05-07 | Univ Bristol | Novel Uses of VEGFxxxb |
US8765941B2 (en) * | 2008-03-25 | 2014-07-01 | Kino Pharma, Inc. | Aniline derivative having anti-RNA viral activity |
JP2012509306A (en) | 2008-11-22 | 2012-04-19 | ザ ユニバーシティ オブ ブリストル | New use of VEGFxxxb |
WO2011036429A1 (en) | 2009-09-25 | 2011-03-31 | The University Of Bristol | Detection of risk of pre-eclampsia |
US20120107304A1 (en) * | 2010-04-27 | 2012-05-03 | Boehringer Ingelheim International Gmbh | Combination therapy in treatment of oncological and fibrotic diseases |
GB201009173D0 (en) | 2010-05-28 | 2010-07-14 | Univ Bristol | Treatment of pain |
WO2012058176A1 (en) * | 2010-10-29 | 2012-05-03 | Schering Corporation | Novel heteroaryl-carboxamide derivatives as pdk1 inhibitors |
GB201406956D0 (en) * | 2014-04-17 | 2014-06-04 | Univ Nottingham | Compounds |
-
2013
- 2013-10-17 ES ES13786300T patent/ES2858511T3/en active Active
- 2013-10-17 CN CN201380065738.XA patent/CN104869990B/en active Active
- 2013-10-17 WO PCT/GB2013/052716 patent/WO2014060763A1/en active Application Filing
- 2013-10-17 JP JP2015537351A patent/JP2016504270A/en active Pending
- 2013-10-17 EP EP13786300.7A patent/EP2908811B1/en active Active
- 2013-10-17 US US14/436,727 patent/US10301264B2/en active Active
- 2013-10-17 AU AU2013333657A patent/AU2013333657B2/en active Active
- 2013-10-17 IN IN3969DEN2015 patent/IN2015DN03969A/en unknown
-
2018
- 2018-08-10 JP JP2018151511A patent/JP6738512B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2013333657B2 (en) | 2018-04-26 |
US20150274668A1 (en) | 2015-10-01 |
AU2013333657A1 (en) | 2015-05-28 |
EP2908811B1 (en) | 2020-12-09 |
JP2018203748A (en) | 2018-12-27 |
EP2908811A1 (en) | 2015-08-26 |
ES2858511T3 (en) | 2021-09-30 |
CN104869990A (en) | 2015-08-26 |
JP2016504270A (en) | 2016-02-12 |
CN104869990B (en) | 2022-12-20 |
US10301264B2 (en) | 2019-05-28 |
WO2014060763A1 (en) | 2014-04-24 |
JP6738512B2 (en) | 2020-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3297644A4 (en) | Methods for treating autism spectrum disorder and associated symptoms | |
HK1222552A1 (en) | Sobetirome in the treatment of myelination diseases | |
IL239368A0 (en) | Ppar-sparing thiazolidiones and combinations for the treatment of neurodegenerative diseases | |
IL225239A0 (en) | Compositions for the treatment of acne and related disorders | |
EP2756740A4 (en) | Cold plasma treatment devices and associated methods | |
MX356525B (en) | Aav -vectors for use in gene therapy of choroideremia. | |
IN2015DN03969A (en) | ||
EP3041577A4 (en) | Treatment and prevention of autism and autism spectrum disorders | |
ZA201300954B (en) | Methods for treating and/or reversing neurodegenerative deseases and/or disorders | |
EP2986308A4 (en) | Angiotensin ii alone or in combination for the treatment of hypotension | |
PL2854910T3 (en) | Ceramide levels in the treatment and prevention of infections | |
IL233141A0 (en) | Combination therapy for treating hearing and balance disorders | |
EP3068492A4 (en) | Neurodegenerative disorders and methods of treatment and diagnosis thereof | |
EP3099638A4 (en) | Wastewater treatment process and system | |
EP2825194A4 (en) | The use of antithrombin in the treatment of pre-eclampsia | |
PH12016501173A1 (en) | Quinazolin-thf-amines as pde1 inhibitors | |
PL3040329T3 (en) | Aromatic compound and use thereof in the treatment of disorders associated with bone metabolism | |
EP2994147A4 (en) | Compositions and methods for the treatment of tinnitus | |
EP2925314A4 (en) | Combination therapeutics and methods for the treatment of neurodegenerative and other diseases | |
MX356052B (en) | Synergistic therapies of cannabidiol with hypothermia for neuroprotection. | |
NZ711523A (en) | Use of sedoheptulose for prevention or treatment of inflammation | |
EP3010524A4 (en) | Protamine in treatment of neuronal injuries | |
AU2018303280A1 (en) | Clusterin for use in the treatment of thrombotic microangiopathies | |
AU2014353885A8 (en) | Prevention and treatment of toxicosis | |
PL2686005T3 (en) | Topical compositions comprising diaminooxidase for the treatment or prevention of diseases associated with high histamine levels which involve an increase in pain |